Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.

Michele ReniUmberto PerettiSilvia ZanonMarina MacchiniGianpaolo BalzanoElena MazzaDomenico TamburrinoGiulia OrsiPaolo Giorgio ArcidiaconoMassimo FalconiLuca Gianni

Published in: Cancer chemotherapy and pharmacology (2020)

The present study suggests that a 4-6 months program might be a more suitable candidate for prospective assessment in comparison to shorter pre-defined period in patients who are candidates to surgery after primary chemotherapy.

Keyphrases

end stage renal disease
minimally invasive
ejection fraction
chronic kidney disease
newly diagnosed
locally advanced
quality improvement
squamous cell carcinoma
patient reported outcomes
coronary artery disease
radiation therapy
protein kinase
replacement therapy